Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.
2 reports, 2 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Eli Lilly's drug is being tested for market approval while also being advertised for illicit sales on TikTok in Brighton.Sub-event
Black market drug sales of GLP-1 products are being intercepted by CBP.1 source
Keep exploring
The entities involved
- FDA
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- The FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.